Long-term outcomes of multimodality management for parasagittal meningiomas
Purpose The aim of this study was to systematically analyze the clinical characteristics of a large cohort of parasagittal meningioma (PM) and to evaluate the patients’ outcomes and best treatment strategies based on tumor features. Methods To minimize selection bias we performed a single-institutio...
Gespeichert in:
Veröffentlicht in: | Journal of neuro-oncology 2020-04, Vol.147 (2), p.441-450 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 450 |
---|---|
container_issue | 2 |
container_start_page | 441 |
container_title | Journal of neuro-oncology |
container_volume | 147 |
creator | Hua, Lingyang Wang, Daijun Zhu, Hongda Deng, Jiaojiao Luan, Shihai Chen, Haixia Sun, Shuchen Tang, Hailiang Xie, Qing Wakimoto, Hiroaki Gong, Ye |
description | Purpose
The aim of this study was to systematically analyze the clinical characteristics of a large cohort of parasagittal meningioma (PM) and to evaluate the patients’ outcomes and best treatment strategies based on tumor features.
Methods
To minimize selection bias we performed a single-institutional review of PM with restricted criteria. One hundred and ninety-two consecutive patients who met criteria for inclusion were reviewed from 2003 to 2011 in our general hospital.
Results
A total of 131 cases (68.2%) were with WHO grade I, while grade II and grade III PMs constituted 40 (20.8%) and 21 cases (10.9%). Higher histological grade was associated with loss of trimethylation of H3K27 (P = 0.000). For WHO grade I PMs, GTR was significantly associated with a better PFS (P = 0.023); however, adjuvant radiotherapy did not benefit patients with STR (P = 0.215). For de novo high-grade (WHO grade II and III) PMs (n = 37), adjuvant radiotherapy was associated with a significantly longer OS (P = 0.013), while no difference was observed between GTR and STR (P = 0.654). In recurrent high-grade PM patients (n = 24), GTR combined with adjuvant radiotherapy increased PFS (P = 0.005).
Conclusions
This study demonstrated that PMs were a heterogeneous group of tumors with a high proportion of high-grade tumors that often displayed aggressive clinical behaviors. Low-grade PM benefited from radical resection, whereas high-grade de novo PM did not. Adjuvant radiotherapy significantly prolonged OS for high-grade primary PM, but did not impact survival of patients with subtotally resected low-grade tumors. Long-term outcome of high-grade recurrent PMs was dismal. We thus show that extent of tumor resection, tumor grade and tumor recurrent status inform therapeutic decisions for PMs. |
doi_str_mv | 10.1007/s11060-020-03440-9 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2363087830</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2363087830</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-bf0a16956c19c15d7c130db96a417bba67224253038cbb34e2abfd777bb8dfc93</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMo7rr6BzxIwYuX6qRJk_Yoi1-44EXBW0jTtHRpmjVJD_vvzdpVwYOHMJB55p3hQegcwzUG4DceY2CQQhYfoRTS8gDNcc5Jygknh2gOmPE0L-n7DJ14vwYAygk-RjOSQVEUmM7R88oObRq0M4kdg7JG-8Q2iRn70Blby74L28TIQbba6CEkjXXJRjrpZduFIPsk_nZD21kj_Sk6amTv9dm-LtDb_d3r8jFdvTw8LW9XqSI8D2nVgMSszJnCpcJ5zRUmUFclkxTzqpKMZxnNcgKkUFVFqM5k1dScx15RN6okC3Q15W6c_Ri1D8J0Xum-l4O2oxcZYQQKXsSEBbr8g67t6IZ4XaQKxqIOxiKVTZRy1nunG7FxnZFuKzCInWoxqRZRtfhSLXZXXOyjx8ro-mfk220EyAT42Bpa7X53_xP7CY63iZ0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2386673166</pqid></control><display><type>article</type><title>Long-term outcomes of multimodality management for parasagittal meningiomas</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Hua, Lingyang ; Wang, Daijun ; Zhu, Hongda ; Deng, Jiaojiao ; Luan, Shihai ; Chen, Haixia ; Sun, Shuchen ; Tang, Hailiang ; Xie, Qing ; Wakimoto, Hiroaki ; Gong, Ye</creator><creatorcontrib>Hua, Lingyang ; Wang, Daijun ; Zhu, Hongda ; Deng, Jiaojiao ; Luan, Shihai ; Chen, Haixia ; Sun, Shuchen ; Tang, Hailiang ; Xie, Qing ; Wakimoto, Hiroaki ; Gong, Ye</creatorcontrib><description>Purpose
The aim of this study was to systematically analyze the clinical characteristics of a large cohort of parasagittal meningioma (PM) and to evaluate the patients’ outcomes and best treatment strategies based on tumor features.
Methods
To minimize selection bias we performed a single-institutional review of PM with restricted criteria. One hundred and ninety-two consecutive patients who met criteria for inclusion were reviewed from 2003 to 2011 in our general hospital.
Results
A total of 131 cases (68.2%) were with WHO grade I, while grade II and grade III PMs constituted 40 (20.8%) and 21 cases (10.9%). Higher histological grade was associated with loss of trimethylation of H3K27 (P = 0.000). For WHO grade I PMs, GTR was significantly associated with a better PFS (P = 0.023); however, adjuvant radiotherapy did not benefit patients with STR (P = 0.215). For de novo high-grade (WHO grade II and III) PMs (n = 37), adjuvant radiotherapy was associated with a significantly longer OS (P = 0.013), while no difference was observed between GTR and STR (P = 0.654). In recurrent high-grade PM patients (n = 24), GTR combined with adjuvant radiotherapy increased PFS (P = 0.005).
Conclusions
This study demonstrated that PMs were a heterogeneous group of tumors with a high proportion of high-grade tumors that often displayed aggressive clinical behaviors. Low-grade PM benefited from radical resection, whereas high-grade de novo PM did not. Adjuvant radiotherapy significantly prolonged OS for high-grade primary PM, but did not impact survival of patients with subtotally resected low-grade tumors. Long-term outcome of high-grade recurrent PMs was dismal. We thus show that extent of tumor resection, tumor grade and tumor recurrent status inform therapeutic decisions for PMs.</description><identifier>ISSN: 0167-594X</identifier><identifier>EISSN: 1573-7373</identifier><identifier>DOI: 10.1007/s11060-020-03440-9</identifier><identifier>PMID: 32088814</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Brain cancer ; Clinical Study ; Combined Modality Therapy ; Disease Management ; Female ; Follow-Up Studies ; Humans ; Male ; Medicine ; Medicine & Public Health ; Meningeal Neoplasms - mortality ; Meningeal Neoplasms - pathology ; Meningeal Neoplasms - therapy ; Meningioma ; Meningioma - mortality ; Meningioma - pathology ; Meningioma - therapy ; Middle Aged ; Neurology ; Oncology ; Patients ; Prognosis ; Radiation therapy ; Retrospective Studies ; Survival Rate ; Tumors ; Young Adult</subject><ispartof>Journal of neuro-oncology, 2020-04, Vol.147 (2), p.441-450</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-bf0a16956c19c15d7c130db96a417bba67224253038cbb34e2abfd777bb8dfc93</citedby><cites>FETCH-LOGICAL-c375t-bf0a16956c19c15d7c130db96a417bba67224253038cbb34e2abfd777bb8dfc93</cites><orcidid>0000-0001-5647-3008</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11060-020-03440-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11060-020-03440-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32088814$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hua, Lingyang</creatorcontrib><creatorcontrib>Wang, Daijun</creatorcontrib><creatorcontrib>Zhu, Hongda</creatorcontrib><creatorcontrib>Deng, Jiaojiao</creatorcontrib><creatorcontrib>Luan, Shihai</creatorcontrib><creatorcontrib>Chen, Haixia</creatorcontrib><creatorcontrib>Sun, Shuchen</creatorcontrib><creatorcontrib>Tang, Hailiang</creatorcontrib><creatorcontrib>Xie, Qing</creatorcontrib><creatorcontrib>Wakimoto, Hiroaki</creatorcontrib><creatorcontrib>Gong, Ye</creatorcontrib><title>Long-term outcomes of multimodality management for parasagittal meningiomas</title><title>Journal of neuro-oncology</title><addtitle>J Neurooncol</addtitle><addtitle>J Neurooncol</addtitle><description>Purpose
The aim of this study was to systematically analyze the clinical characteristics of a large cohort of parasagittal meningioma (PM) and to evaluate the patients’ outcomes and best treatment strategies based on tumor features.
Methods
To minimize selection bias we performed a single-institutional review of PM with restricted criteria. One hundred and ninety-two consecutive patients who met criteria for inclusion were reviewed from 2003 to 2011 in our general hospital.
Results
A total of 131 cases (68.2%) were with WHO grade I, while grade II and grade III PMs constituted 40 (20.8%) and 21 cases (10.9%). Higher histological grade was associated with loss of trimethylation of H3K27 (P = 0.000). For WHO grade I PMs, GTR was significantly associated with a better PFS (P = 0.023); however, adjuvant radiotherapy did not benefit patients with STR (P = 0.215). For de novo high-grade (WHO grade II and III) PMs (n = 37), adjuvant radiotherapy was associated with a significantly longer OS (P = 0.013), while no difference was observed between GTR and STR (P = 0.654). In recurrent high-grade PM patients (n = 24), GTR combined with adjuvant radiotherapy increased PFS (P = 0.005).
Conclusions
This study demonstrated that PMs were a heterogeneous group of tumors with a high proportion of high-grade tumors that often displayed aggressive clinical behaviors. Low-grade PM benefited from radical resection, whereas high-grade de novo PM did not. Adjuvant radiotherapy significantly prolonged OS for high-grade primary PM, but did not impact survival of patients with subtotally resected low-grade tumors. Long-term outcome of high-grade recurrent PMs was dismal. We thus show that extent of tumor resection, tumor grade and tumor recurrent status inform therapeutic decisions for PMs.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Brain cancer</subject><subject>Clinical Study</subject><subject>Combined Modality Therapy</subject><subject>Disease Management</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Meningeal Neoplasms - mortality</subject><subject>Meningeal Neoplasms - pathology</subject><subject>Meningeal Neoplasms - therapy</subject><subject>Meningioma</subject><subject>Meningioma - mortality</subject><subject>Meningioma - pathology</subject><subject>Meningioma - therapy</subject><subject>Middle Aged</subject><subject>Neurology</subject><subject>Oncology</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Radiation therapy</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>0167-594X</issn><issn>1573-7373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kE1LxDAQhoMo7rr6BzxIwYuX6qRJk_Yoi1-44EXBW0jTtHRpmjVJD_vvzdpVwYOHMJB55p3hQegcwzUG4DceY2CQQhYfoRTS8gDNcc5Jygknh2gOmPE0L-n7DJ14vwYAygk-RjOSQVEUmM7R88oObRq0M4kdg7JG-8Q2iRn70Blby74L28TIQbba6CEkjXXJRjrpZduFIPsk_nZD21kj_Sk6amTv9dm-LtDb_d3r8jFdvTw8LW9XqSI8D2nVgMSszJnCpcJ5zRUmUFclkxTzqpKMZxnNcgKkUFVFqM5k1dScx15RN6okC3Q15W6c_Ri1D8J0Xum-l4O2oxcZYQQKXsSEBbr8g67t6IZ4XaQKxqIOxiKVTZRy1nunG7FxnZFuKzCInWoxqRZRtfhSLXZXXOyjx8ro-mfk220EyAT42Bpa7X53_xP7CY63iZ0</recordid><startdate>20200401</startdate><enddate>20200401</enddate><creator>Hua, Lingyang</creator><creator>Wang, Daijun</creator><creator>Zhu, Hongda</creator><creator>Deng, Jiaojiao</creator><creator>Luan, Shihai</creator><creator>Chen, Haixia</creator><creator>Sun, Shuchen</creator><creator>Tang, Hailiang</creator><creator>Xie, Qing</creator><creator>Wakimoto, Hiroaki</creator><creator>Gong, Ye</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5647-3008</orcidid></search><sort><creationdate>20200401</creationdate><title>Long-term outcomes of multimodality management for parasagittal meningiomas</title><author>Hua, Lingyang ; Wang, Daijun ; Zhu, Hongda ; Deng, Jiaojiao ; Luan, Shihai ; Chen, Haixia ; Sun, Shuchen ; Tang, Hailiang ; Xie, Qing ; Wakimoto, Hiroaki ; Gong, Ye</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-bf0a16956c19c15d7c130db96a417bba67224253038cbb34e2abfd777bb8dfc93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Brain cancer</topic><topic>Clinical Study</topic><topic>Combined Modality Therapy</topic><topic>Disease Management</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Meningeal Neoplasms - mortality</topic><topic>Meningeal Neoplasms - pathology</topic><topic>Meningeal Neoplasms - therapy</topic><topic>Meningioma</topic><topic>Meningioma - mortality</topic><topic>Meningioma - pathology</topic><topic>Meningioma - therapy</topic><topic>Middle Aged</topic><topic>Neurology</topic><topic>Oncology</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Radiation therapy</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hua, Lingyang</creatorcontrib><creatorcontrib>Wang, Daijun</creatorcontrib><creatorcontrib>Zhu, Hongda</creatorcontrib><creatorcontrib>Deng, Jiaojiao</creatorcontrib><creatorcontrib>Luan, Shihai</creatorcontrib><creatorcontrib>Chen, Haixia</creatorcontrib><creatorcontrib>Sun, Shuchen</creatorcontrib><creatorcontrib>Tang, Hailiang</creatorcontrib><creatorcontrib>Xie, Qing</creatorcontrib><creatorcontrib>Wakimoto, Hiroaki</creatorcontrib><creatorcontrib>Gong, Ye</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuro-oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hua, Lingyang</au><au>Wang, Daijun</au><au>Zhu, Hongda</au><au>Deng, Jiaojiao</au><au>Luan, Shihai</au><au>Chen, Haixia</au><au>Sun, Shuchen</au><au>Tang, Hailiang</au><au>Xie, Qing</au><au>Wakimoto, Hiroaki</au><au>Gong, Ye</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term outcomes of multimodality management for parasagittal meningiomas</atitle><jtitle>Journal of neuro-oncology</jtitle><stitle>J Neurooncol</stitle><addtitle>J Neurooncol</addtitle><date>2020-04-01</date><risdate>2020</risdate><volume>147</volume><issue>2</issue><spage>441</spage><epage>450</epage><pages>441-450</pages><issn>0167-594X</issn><eissn>1573-7373</eissn><abstract>Purpose
The aim of this study was to systematically analyze the clinical characteristics of a large cohort of parasagittal meningioma (PM) and to evaluate the patients’ outcomes and best treatment strategies based on tumor features.
Methods
To minimize selection bias we performed a single-institutional review of PM with restricted criteria. One hundred and ninety-two consecutive patients who met criteria for inclusion were reviewed from 2003 to 2011 in our general hospital.
Results
A total of 131 cases (68.2%) were with WHO grade I, while grade II and grade III PMs constituted 40 (20.8%) and 21 cases (10.9%). Higher histological grade was associated with loss of trimethylation of H3K27 (P = 0.000). For WHO grade I PMs, GTR was significantly associated with a better PFS (P = 0.023); however, adjuvant radiotherapy did not benefit patients with STR (P = 0.215). For de novo high-grade (WHO grade II and III) PMs (n = 37), adjuvant radiotherapy was associated with a significantly longer OS (P = 0.013), while no difference was observed between GTR and STR (P = 0.654). In recurrent high-grade PM patients (n = 24), GTR combined with adjuvant radiotherapy increased PFS (P = 0.005).
Conclusions
This study demonstrated that PMs were a heterogeneous group of tumors with a high proportion of high-grade tumors that often displayed aggressive clinical behaviors. Low-grade PM benefited from radical resection, whereas high-grade de novo PM did not. Adjuvant radiotherapy significantly prolonged OS for high-grade primary PM, but did not impact survival of patients with subtotally resected low-grade tumors. Long-term outcome of high-grade recurrent PMs was dismal. We thus show that extent of tumor resection, tumor grade and tumor recurrent status inform therapeutic decisions for PMs.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>32088814</pmid><doi>10.1007/s11060-020-03440-9</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-5647-3008</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0167-594X |
ispartof | Journal of neuro-oncology, 2020-04, Vol.147 (2), p.441-450 |
issn | 0167-594X 1573-7373 |
language | eng |
recordid | cdi_proquest_miscellaneous_2363087830 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | Adolescent Adult Aged Aged, 80 and over Brain cancer Clinical Study Combined Modality Therapy Disease Management Female Follow-Up Studies Humans Male Medicine Medicine & Public Health Meningeal Neoplasms - mortality Meningeal Neoplasms - pathology Meningeal Neoplasms - therapy Meningioma Meningioma - mortality Meningioma - pathology Meningioma - therapy Middle Aged Neurology Oncology Patients Prognosis Radiation therapy Retrospective Studies Survival Rate Tumors Young Adult |
title | Long-term outcomes of multimodality management for parasagittal meningiomas |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T15%3A08%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20outcomes%20of%20multimodality%20management%20for%20parasagittal%20meningiomas&rft.jtitle=Journal%20of%20neuro-oncology&rft.au=Hua,%20Lingyang&rft.date=2020-04-01&rft.volume=147&rft.issue=2&rft.spage=441&rft.epage=450&rft.pages=441-450&rft.issn=0167-594X&rft.eissn=1573-7373&rft_id=info:doi/10.1007/s11060-020-03440-9&rft_dat=%3Cproquest_cross%3E2363087830%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2386673166&rft_id=info:pmid/32088814&rfr_iscdi=true |